Skip to main content
. Author manuscript; available in PMC: 2014 Nov 24.
Published in final edited form as: Invest New Drugs. 2013 Feb 8;31(5):1142–1150. doi: 10.1007/s10637-013-9932-0

Fig. 5.

Fig. 5

Dose-dependent B16F10 tumor growth inhibition by PTX013 treatment. a Dose-dependent B16F10 tumor growth inhibition by 1.5, 5, and 10 mg/kg (BID IP for 7 days) treatment of PTX013. b Body weights of the mice during PTX013 treatment (1.5, 5, and 10 mg/kg BID IP for 7 days). c Dose-dependent B16F10 tumor growth inhibition by 0.1, 0.2, and 0.5 mg/kg (BID IP for 7 days) PTX013 treatment. d Body weights of the mice during PTX013 treatment (0.1, 0.2, and 0.5 mg/kg BID IP for 7 days). Data points represent means±SEM (n= 10–20 each group)